author-photo

Lina Yin

Merck & Co.

5

Papers

145

Citations

Citation Trend

Filter By

Papers (2) Sort By

Journal Conference Others

Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced renal cell carcinoma (RCC): Updated analysis of KEYNOTE-426.

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (37)
Randomized, double-blind, phase 3 trial of first-line pembrolizumab + platinum doublet chemotherapy (chemo) ± lenvatinib in patients (pts) with metastatic nonsquamous non–small-cell lung cancer (NSCLC): LEAP-006.

2019 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (4)